These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20020494)

  • 1. Inhibition of immune responses by Dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo.
    Chen J
    Int J Cancer; 2010 Sep; 127(5):1249-50; author reply 1250-1. PubMed ID: 20020494
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.
    Vitali R; Mancini C; Cesi V; Tanno B; Piscitelli M; Mancuso M; Sesti F; Pasquali E; Calabretta B; Dominici C; Raschellà G
    Int J Cancer; 2009 Dec; 125(11):2547-55. PubMed ID: 19623650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
    Fraser CK; Blake SJ; Diener KR; Lyons AB; Brown MP; Hughes TP; Hayball JD
    Exp Hematol; 2009 Feb; 37(2):256-65. PubMed ID: 19056158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.
    Timeus F; Crescenzio N; Fandi A; Doria A; Foglia L; Cordero di Montezemolo L
    Oncol Rep; 2008 Feb; 19(2):353-9. PubMed ID: 18202781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S; Hughes TP; Mayrhofer G; Lyons AB
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.
    Jönsson S; Hjorth-Hansen H; Olsson B; Wadenvik H; Sundan A; Standal T
    Leukemia; 2010 Jul; 24(7):1357-9. PubMed ID: 20485368
    [No Abstract]   [Full Text] [Related]  

  • 7. PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
    Tobío A; Alfonso A; Botana LM
    Anticancer Res; 2014 Jul; 34(7):3347-56. PubMed ID: 24982339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells.
    Shapira S; Granot G; Mor-Tzuntz R; Raanani P; Uziel O; Lahav M; Shpilberg O
    Cancer Lett; 2012 Oct; 323(2):223-31. PubMed ID: 22554713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
    Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
    Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).
    Chen Z; Lee FY; Bhalla KN; Wu J
    Mol Pharmacol; 2006 May; 69(5):1527-33. PubMed ID: 16436588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New assignments for multitasking signal transduction inhibitors.
    Zhang Z; Meier KE
    Mol Pharmacol; 2006 May; 69(5):1510-2. PubMed ID: 16497876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine.
    Umazume K; Liu L; Scott PA; de Castro JP; McDonald K; Kaplan HJ; Tamiya S
    Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1150-9. PubMed ID: 23341014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
    Johnson FM; Saigal B; Tran H; Donato NJ
    Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.